NCT02340611View on ClinicalTrials.gov

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Ovarian Cancer
Interventions
DRUG

Olaparib

Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor

DRUG

Cediranib

Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University Health Network, Toronto

OTHER